Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Deffered Revenue: 2021-2025

Historic Non-Current Deffered Revenue for Autolus Therapeutics (AUTL) over the last 3 years, with Mar 2025 value amounting to $253.4 million.

  • Autolus Therapeutics' Non-Current Deffered Revenue rose 10.92% to $253.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $253.4 million, marking a year-over-year increase of 10.92%. This contributed to the annual value of $244.6 million for FY2024, which is 43.13% up from last year.
  • According to the latest figures from Q1 2025, Autolus Therapeutics' Non-Current Deffered Revenue is $253.4 million, which was up 3.61% from $244.6 million recorded in Q4 2024.
  • Autolus Therapeutics' 5-year Non-Current Deffered Revenue high stood at $253.4 million for Q1 2025, and its period low was $47.0 million during Q4 2021.
  • Over the past 3 years, Autolus Therapeutics' median Non-Current Deffered Revenue value was $228.5 million (recorded in 2024), while the average stood at $199.2 million.
  • Data for Autolus Therapeutics' Non-Current Deffered Revenue shows a peak YoY soared of 168.44% (in 2023) over the last 5 years.
  • Autolus Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $47.0 million in 2021, then soared by 167.78% to $125.9 million in 2022, then surged by 35.74% to $170.9 million in 2023, then skyrocketed by 43.13% to $244.6 million in 2024, then climbed by 10.92% to $253.4 million in 2025.
  • Its Non-Current Deffered Revenue was $253.4 million in Q1 2025, compared to $244.6 million in Q4 2024 and $248.9 million in Q3 2024.